Mutant p53: One, No One, and One Hundred Thousand

Frontiers in Oncology

Volumn 5, Issue DEC, 2015, Pages

  Walerych, Dawid ^a   Lisek, Kamil ^a,b   Del Sal, Giannino ^a,b  

^a Laboratorio Nazionale CIB   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cancer; Combination; Drug therapy; Gain of function; Oncogenes; p53 mutation; Tumor suppressor proteins

Indexed keywords

CISPLATIN; DNA BINDING PROTEIN; MUTANT PROTEIN; PROTEIN P53; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

CANCER GENETICS; DNA SEQUENCE; FAMILIAL CANCER; GAIN OF FUNCTION MUTATION; GENE DELETION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HUMAN; MISSENSE MUTATION; MUTANT; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

EID: 84954556659     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00289     Document Type: Short Survey

References (81)

1. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer (2011) 2:466-74. doi: 10.1177/1947601911408889.
2. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature (2013) 502:333-9. doi:10.1038/nature12634.
3. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 9:701-13. doi:10.1038/nrc2693.
4. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev (2012) 26:1268-86. doi:10.1101/gad.190678.112.
5. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 33:2007-17. doi:10.1093/carcin/bgs232.
6. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 25:304-17. doi:10.1016/j.ccr.2014.01.021.
7. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 28:622-9. doi:10.1002/humu.20495.
8. Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res (2011) 110:107-39. doi:10.1016/B978-0-12-386469-7.00005-0.
9. Malkin D. Li-Fraumeni syndrome. Genes Cancer (2011) 2:475-84. doi:10.1177/1947601911413466.
10. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 265:346-55. doi:10.1126/science.8023157.
11. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene (2000) 19:1245-56. doi:10.1038/sj.onc.1203434.
12. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 119:847-60. doi:10.1016/j.cell.2004.11.004.
13. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene (1997) 14:865-71. doi:10.1038/sj.onc.1201041.
14. Schlegelberger B, Kreipe H, Lehmann U, Steinemann D, Ripperger T, Gohring G, et al. A child with Li-Fraumeni syndrome: modes to inactivate the second allele of TP53 in three different malignancies. Pediatr Blood Cancer (2015) 62:1481-4. doi:10.1002/pbc.25486.
15. Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, et al. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ (2014) 21:1419-31. doi:10.1038/cdd.2014.57.
16. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 22:1337-44. doi:10.1101/gad.1662908.
17. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 71:7168-75. doi:10.1158/0008-5472.CAN-11-0459.
18. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 119:861-72. doi:10.1016/j.cell.2004.11.006.
19. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 250:113-6. doi:10.1126/science.2218501.
20. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genet (1993) 4:42-6. doi:10.1038/ng0593-42.
21. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 9:573-80. doi:10.1038/ncb1571.
22. Weissmueller S, Manchado E, Saborowski M, Morris JPT, Wagenblast E, Davis CA, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell (2014) 157:382-94. doi:10.1016/j.cell.2014.01.066.
23. Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A (2014) 111:11145-50. doi:10.1073/pnas.1404139111.
24. Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ, Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell (2012) 22:751-64. doi:10.1016/j.ccr.2012.10.022.
25. Yan W, Chen X. Characterization of functional domains necessary for mutant p53 gain of function. J Biol Chem (2010) 285:14229-38. doi:10.1074/jbc. M109.097253.
26. Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, et al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun (2015) 6:7389. doi:10.1038/ncomms8389.
27. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature (2015) 525:206-11. doi:10.1038/nature15251.
28. Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, et al. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle (2008) 7:3440-7. doi:10.4161/cc.7.21.6995.
29. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 137:87-98. doi:10.1016/j.cell.2009.01.039.
30. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 10:191-202. doi:10.1016/j.ccr.2006.08.013.
31. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, et al. A pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 20:79-91. doi:10.1016/j.ccr.2011.06.004.
32. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 17:273-85. doi:10.1016/j.ccr.2009.11.025.
33. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 148:244-58. doi:10.1016/j.cell.2011.12.017.
34. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol (2009) 16:1086-93. doi:10.1038/nsmb.1669.
35. Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev (2012) 26:830-45. doi:10.1101/gad.181685.111.
36. Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell (2014) 56:617-29. doi:10.1016/j.molcel.2014.10.013.
37. Coffill CR, Muller PA, Oh HK, Neo SP, Hogue KA, Cheok CF, et al. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep (2012) 13:638-44. doi:10.1038/embor.2012.74.
38. Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, et al. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A (2015) 112(11):E1220-9. doi:10.1073/pnas.1416318112.
39. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 139:1327-41. doi:10.1016/j.cell.2009.11.026.
40. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 25:10097-110. doi:10.1128/MCB.25.22.10097-10110.2005.
41. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun (2013) 4:2935. doi:10.1038/ncomms3935.
42. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 2(12):1203-17. doi:10.18632/oncotarget.382.
43. Liu K, Ling S, Lin WC. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol (2011) 31:4464-81. doi:10.1128/MCB.05574-11.
44. Chowdhury P, Lin GE, Liu K, Song Y, Lin FT, Lin WC. Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. Nat Commun (2014) 5:5476. doi:10.1038/ncomms6476.
45. Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci (2012) 125:3144-52. doi:10.1242/jcs.099663.
46. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol (2014) 16:357-66. doi:10.1038/ncb2936.
47. Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, et al. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep (2015).
48. Zhang Y, Yan W, Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem (2011) 286:16218-28. doi:10.1074/jbc. M110.214585.
49. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 25:304-9. doi:10.1038/sj.onc.1209026.
50. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A (1996) 93:8379-83. doi:10.1073/pnas.93.16.8379.
51. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene (1995) 11:933-9.
52. Dasgupta G, Momand J. Geldanamycin prevents nuclear translocation of mutant p53. Exp Cell Res (1997) 237:29-37. doi:10.1006/excr.1997.3766.
53. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature (2015) 523:352-6. doi:10.1038/nature14430.
54. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ (2011) 18(12):1904-13. doi:10.1038/cdd.2011.71.
55. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene (2013) 32:599-609. doi:10.1038/onc.2012.81.
56. Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med (2015) 21:457-66. doi:10.1038/nm.3839.
57. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med (1997) 3:632-8. doi:10.1038/nm0697-632.
58. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 99:937-42. doi:10.1073/pnas.241629998.
59. Guida E, Bisso A, Fenollar-Ferrer C, Napoli M, Anselmi C, Girardini JE, et al. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res (2008) 68:6550-8. doi:10.1158/0008-5472.CAN-08-0137.
60. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science (1999) 286:2507-10. doi:10.1126/science.286.5449.2507.
61. He X, Kong X, Yan J, Zhang Y, Wu Q, Chang Y, et al. CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo. Tumour Biol (2015) 36:1437-44. doi:10.1007/s13277-014-2389-8.
62. Li P, Zhao M, Parris AB, Feng X, Yang X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochem Biophys Res Commun (2015) 464:1267-74. doi:10.1016/j.bbrc.2015.07.117.
63. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 8:282-8. doi:10.1038/nm0302-282.
64. Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett (2014) 588:2622-7. doi:10.1016/j.febslet.2014.04.017.
65. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 15:376-88. doi:10.1016/j.ccr.2009.03.003.
66. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol (2008) 30:411-8. doi:10.3233/CLO-2008-0440.
67. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene (2010) 29:1329-38. doi:10.1038/onc.2009.425.
68. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell (2012) 21:614-25. doi:10.1016/j.ccr.2012.03.042.
69. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 105:10360-5. doi:10.1073/pnas.0805326105.
70. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 41:6034-44. doi:10.1093/nar/gkt305.
71. Girardini JE, Marotta C, Del Sal G. Disarming mutant p53 oncogenic function. Pharmacol Res (2014) 79:75-87. doi:10.1016/j.phrs.2013.11.003.
72. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 30:3633-9. doi:10.1200/JCO.2011.40.7783.
73. Ma CX, Cai S, Li S, Ryan CE, Guo Z, SchaiffWT, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 122:1541-52. doi:10.1172/JCI58765.
74. Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene (2013) 32:577-88. doi:10.1038/onc.2012.84.
75. Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat (2013) 137:483-92. doi:10.1007/s10549-012-2378-9.
76. Gonyeau MJ. The spectrum of statin therapy in cancer patients: is there a need for further investigation? Curr Atheroscler Rep (2014) 16:383. doi:10.1007/s11883-013-0383-z.
77. Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov (2014) 9:1-20. doi:10.2174/15748928113089990031.
78. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 124:30-9. doi:10.1172/JCI69738.
79. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 24:3484-91. doi:10.1038/sj.onc.1208419.
80. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, et al. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer (2012) 130:2259-70. doi:10.1002/ijc.26228.
81. Kobayashi N, Abedini M, Sakuragi N, Tsang BK. PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. J Ovarian Res (2013) 6:7. doi:10.1186/1757-2215-6-7.